Cencora (COR) Stock Forecast & Price Target

$298.07 -4.43 (-1.46%)

Closing price 07/8/2025 03:59 PM Eastern

Extended Trading

$295.65 -2.42 (-0.81%)

As of 07/8/2025 06:17 PM Eastern

Cencora - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
2

Buy
9

Based on 11 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 2 have given a hold rating, and 9 have given a buy rating for COR.

Consensus Price Target

$306.33
2.77% Upside

According to the 11 analysts' twelve-month price targets for Cencora, the average price target is $306.33. The highest price target for COR is $355.00, while the lowest price target for COR is $275.00. The average price target represents a forecasted upside of 2.77% from the current price of $298.07.

Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

COR Analyst Ratings Over Time

Type	Current Forecast 7/9/24 to 7/9/25	1 Month Ago 6/9/24 to 6/9/25	3 Months Ago 4/10/24 to 4/10/25	1 Year Ago 7/10/23 to 7/9/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$306.33	$306.91	$280.20	$236.10
Forecasted Upside	2.77% Upside	8.09% Upside	0.42% Upside	6.17% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cencora Stock vs. The Competition

Type	Cencora	Medical Companies	S&P 500
Consensus Rating Score	2.82	2.80	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	2.77% Upside	9,164.86% Upside	10.40% Upside
News Sentiment Rating	Positive News See Recent COR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/30/2025	Jefferies Financial Group 2 of 5 stars	Jonathan Petersen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$275.00 ➝ $300.00	+0.55%
6/3/2025	Wells Fargo & Company 3 of 5 stars	Stephen Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$274.00 ➝ $337.00	+15.37%
5/8/2025	Citigroup 3 of 5 stars	Michael Rollins Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$330.00 ➝ $355.00	+23.80%
5/8/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Rodgers Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$314.00 ➝ $350.00	+15.12%
4/29/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$298.00 ➝ $335.00	+16.26%
4/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$288.00	+1.22%
4/11/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Funk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$270.00 ➝ $285.00	+2.14%
2/6/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	John Belton Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$270.00 ➝ $280.00	+12.80%
1/24/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$289.00 ➝ $301.00	+21.13%
12/4/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform	$280.00	+11.98%
Get the Latest News and Ratings for COR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.
11/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$263.00 ➝ $290.00	+18.18%
10/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$277.00 ➝ $275.00	+25.03%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/7/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$205.00 ➝ $215.00	+15.07%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:09 AM ET.

Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 7, 2025. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

The current stock price is around $302, reflecting a strong market position and investor confidence in the company's growth potential.
Institutional investors own a significant majority of the stock, indicating strong support and confidence from large financial entities.
Recent insider transactions show that key executives are actively managing their holdings, which can signal confidence in the company's future performance.
Cencora, Inc. has demonstrated a solid market capitalization of approximately $58.62 billion, suggesting a stable financial foundation for growth.
The company has a relatively low beta of 0.57, indicating that its stock is less volatile compared to the market, which can be appealing for risk-averse investors.

Cencora
Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

Recent insider sales, including significant transactions by the chairman and CEO, may raise concerns about the company's future outlook and management's confidence.
There has been a notable decrease in positions held by some institutional investors, which could indicate a lack of confidence in the stock's short-term performance.
The stock has experienced fluctuations, with a 52-week high of $309.35 and a low of $218.65, suggesting potential volatility that could deter some investors.
The price-to-earnings (P/E) ratio of around 35.08 may be considered high, indicating that the stock could be overvalued compared to its earnings, which might concern value investors.
Recent reports indicate that some hedge funds have reduced their stakes, which could signal a bearish sentiment among certain market participants.

COR Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $306.33, with a high forecast of $355.00 and a low forecast of $275.00.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COR shares.
: According to analysts, Cencora's stock has a predicted upside of 2.77% based on their 12-month stock forecasts.
: Over the previous 90 days, Cencora's stock had 1 upgrade by analysts.
: Cencora has been rated by research analysts at Bank of America, Citigroup, Jefferies Financial Group, Morgan Stanley, Robert W. Baird, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Cencora more than other "medical" companies. The consensus rating score for Cencora is 2.82 while the average consensus rating score for "medical" companies is 2.80. Learn more on how COR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:COR) was last updated on 7/9/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Stock Forecast & Price Target